Literature DB >> 33845076

Positive allosteric modulation of type 1 cannabinoid receptors reduces spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg.

Andrew J Roebuck1, Quentin Greba2, Anna-Maria Smolyakova3, Mariam Alaverdashvili3, Wendie N Marks2, Sumanta Garai4, Samantha L Baglot5, Gavin Petrie5, Stuart M Cain6, Terrance P Snutch6, Ganesh A Thakur4, Matthew N Hill5, John G Howland7, Robert B Laprairie8.   

Abstract

Childhood Absence Epilepsy (CAE) accounts for approximately 10% of all pediatric epilepsies. Current treatments for CAE are ineffective in approximately 1/3 of patients and can be associated with severe side effects such as hepatotoxicity. Certain cannabinoids, such as cannabidiol (CBD), have shown promise in the treatment of pediatric epilepsies. However, CBD remains limited or prohibited in many jurisdictions, and has not been shown to have efficacy in CAE. Modulation of the type 1 cannabinoid receptor (CB1R) may provide more desirable pharmacological treatments. Genetic Absence Epilepsy Rats from Strasbourg (GAERS) model many aspects of CAE, including cortical spike and wave discharges (SWDs). We have recently demonstrated that Δ9-tetrahydrocannabinol (THC) increases SWDs in GAERS whereas CBD decreases these events. Here, we characterized aspects of the endocannabinoid system in brain areas relevant to seizures in GAERS and tested whether positive allosteric modulators (PAMs) of CB1R reduced SWDs. Both female and male GAERS had reduced (>50%) expression of CB1R and elevated levels of the endocannabinoid 2-AG in cortex compared to non-epileptic controls (NEC). We then administered the CB1R PAMs GAT211 and GAT229 to GAERS implanted with cortical electrodes. Systemic administration of GAT211 to male GAERS reduced SWDs by 40%. Systemic GAT229 administration reduced SWDs in female and male GAERS. Intracerebral infusion of GAT229 into the cortex of male GAERS reduced SWDs by >60% in a CB1R-dependent manner that was blocked by SR141716A. Together, these experiments identify altered endocannabinoid tone in GAERS and suggest that CB1R PAMs should be explored for treatment of absence seizures.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Animal model; Cannabinoid; Electroencephalogram; Epilepsy; Positive allosteric modulator; Type 1 cannabinoid receptor

Mesh:

Substances:

Year:  2021        PMID: 33845076     DOI: 10.1016/j.neuropharm.2021.108553

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  9 in total

1.  The endocannabinoid system impacts seizures in a mouse model of Dravet syndrome.

Authors:  Lyndsey L Anderson; Peter T Doohan; Nicole A Hawkins; Dilara Bahceci; Sumanta Garai; Ganesh A Thakur; Jennifer A Kearney; Jonathon C Arnold
Journal:  Neuropharmacology       Date:  2021-11-22       Impact factor: 5.273

2.  Cannabinoid 1/2 Receptor Activation Induces Strain-Dependent Behavioral and Neurochemical Changes in Genetic Absence Epilepsy Rats From Strasbourg and Non-epileptic Control Rats.

Authors:  Philippe De Deurwaerdère; Maurizio Casarrubea; Daniel Cassar; Manuela Radic; Emilie Puginier; Abdeslam Chagraoui; Giuseppe Crescimanno; Vincenzo Crunelli; Giuseppe Di Giovanni
Journal:  Front Cell Neurosci       Date:  2022-05-23       Impact factor: 6.147

3.  ACEA Attenuates Oxidative Stress by Promoting Mitophagy via CB1R/Nrf1/PINK1 Pathway after Subarachnoid Hemorrhage in Rats.

Authors:  Binbing Liu; Yang Tian; Yuchen Li; Pei Wu; Yongzhi Zhang; Jiaolin Zheng; Huaizhang Shi
Journal:  Oxid Med Cell Longev       Date:  2022-02-24       Impact factor: 6.543

4.  The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg.

Authors:  Dan L McElroy; Andrew J Roebuck; Quentin Greba; Sumanta Garai; Asher L Brandt; Orhan Yilmaz; Stuart M Cain; Terrance P Snutch; Ganesh A Thakur; Robert B Laprairie; John G Howland
Journal:  IBRO Neurosci Rep       Date:  2022-01-24

5.  Behavioral and Molecular Responses to Exogenous Cannabinoids During Pentylenetetrazol-Induced Convulsions in Male and Female Rats.

Authors:  Antonella Zirotti Rosenberg; Maxs Méndez-Ruette; Mario Gorziglia; Benjamín Alzerreca; Javiera Cabello; Sofía Kaufmann; Lukas Rambousek; Andrés Iturriaga Jofré; Ursula Wyneken; Carlos A Lafourcade
Journal:  Front Mol Neurosci       Date:  2022-08-09       Impact factor: 6.261

6.  The effect of cannabinoid receptor agonist WIN 55,212-2 on anxiety-like behavior and locomotion in a genetic model of absence seizures in the elevated plus-maze.

Authors:  Daniel Cassar; Manuela Radic; Maurizio Casarrubea; Vincenzo Crunelli; Giuseppe Di Giovanni
Journal:  CNS Neurosci Ther       Date:  2022-04-26       Impact factor: 7.035

7.  Cannabinoid receptors distribution in mouse cortical plasma membrane compartments.

Authors:  Hajar Miranzadeh Mahabadi; Haseeb Bhatti; Robert B Laprairie; Changiz Taghibiglou
Journal:  Mol Brain       Date:  2021-06-07       Impact factor: 4.041

Review 8.  Endocannabinoid-Mediated Control of Neural Circuit Excitability and Epileptic Seizures.

Authors:  Yuki Sugaya; Masanobu Kano
Journal:  Front Neural Circuits       Date:  2022-01-03       Impact factor: 3.492

Review 9.  CB1 Cannabinoid Receptor Signaling and Biased Signaling.

Authors:  Luciana M Leo; Mary E Abood
Journal:  Molecules       Date:  2021-09-06       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.